Galvus licensed as monotherapy for type II diabetes

Galvus (vildagliptin) is now licensed as monotherapy for the treatment of type II diabetes in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

Galvus as monotherapy now an option in type II diabetes
Galvus as monotherapy now an option in type II diabetes

In studies as monotherapy, vildagliptin improved glycaemic control whilst being generally well tolerated compared with placebo, metformin and gliclazide. It had minimal effect on weight gain.

Galvus is also licensed for dual therapy of type II diabetes and has recently been approved for use in patients with renal impairment.

View Galvus drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A man with his sleeves rolled up sits in a bare room heating heroin in a spoon over a lighter flame.

New implant treats opioid dependence for 6 months

Patients with opioid dependence can now be given a...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...